Article
Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms.
Blood cancer journal - 10 Jul 2023
Courdy Charly, Platteeuw Loïc, Ducau Charlotte, De Araujo Isabelle, Boet Emeline, Sahal Ambrine, Saland Estelle, Edmond Valérie, Tavitian Suzanne, Bertoli Sarah, Cougoul Pierre, Granat Fanny, Poillet Laura, Marty Caroline, Plo Isabelle, Sarry Jean-Emmanuel, Manenti Stéphane, Mansat-De Mas Véronique, Joffre Carine
Abstract excerpt
The Janus kinase 2 (JAK2)-driven myeloproliferative neoplasms (MPNs) are chronic malignancies associated with high-risk complications and suboptimal responses to JAK inhibitors such as ruxolitinib. A better understanding of cellular changes induced by ruxolitinib is required to develop new combinatory therapies to improve treatment efficacy. Here, we demonstrate that ruxolitinib induced autophagy in JAK2V617F...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.